Expert on Site: Dr. Jonathan Barratt on Sibeprenlimab for IgAN
By Jonathan Barratt, PhD, Joel M. Topf, MD, FACP - Last Updated: November 8, 2024Jonathan Barratt, PhD, is a professor and lead of the renal research group at the University of Leicester. He is lead author of “The Anti-APRIL Antibody Sibeprenlimab Reduced Circulating Immune Complexes in Patients With IgA Nephropathy in the Phase 2 ENVISION Randomized Controlled Trial,” which was presented at ASN Kidney Week 2024.
Advertisement
In this exclusive Expert on Site video, Joel Topf, MD, spoke with Dr. Barratt at Kidney Week about the findings on this anti-APRIL IgAN treatment.
Advertisement
Related Posts
Obinutuzumab reduced proteinuria in patients with FSGS who were treatment-resistant or on immunosuppressive therapy.
RGLS8429 increases urinary PC1 and PC2 proteins, which may help reduce height-adjusted total kidney volume in ADPKD.
Researchers evaluated the efficacy of sparsentan in a subset of patients with genetic focal segmental glomerulosclerosis.
Could pravastatin slow the rate of increase in height-adjusted total kidney volume in adults with ADPKD?
A study examined the efficacy of adding SZC to allow patients with stage 3-4 DKD to maintain treatment with RAASi.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.